Scarica l'app Stockscreener
25.66
0.75%
0.19
Pre-mercato:
25.91
0.25
+0.97%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$25.47
Aprire:
$25.54
Volume 24 ore:
12.21M
Relative Volume:
1.17
Capitalizzazione di mercato:
$9.98B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-2.9393
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
-6.59%
1M Prestazione:
-23.72%
6M Prestazione:
-15.97%
1 anno Prestazione:
-68.43%
Intervallo 1D:
$25.32
$26.26
Intervallo di 1 settimana:
$25.30
$27.48
Portata 52W:
$23.15
$91.99
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
25.66 | 9.91B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna, Teleflex, Envista, Enovis, and UnitedHealth Shares Are Soaring, What You Need To Know - TradingView
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency - Benzinga
Mitsubishi UFJ Asset Management Co. Ltd. Grows Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Vanguard Group Inc. Boosts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (MRNA)’s “Got The Double Whammy,” Says Jim Cramer - MSN
Day 5 of Loss Streak for Moderna Stock with -7.9% Return (vs. -39% YTD) [8/11/2025] - Trefis
Moderna, Inc. (MRNA) stock price, news, quote and history - uk.finance.yahoo.com
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply - Benzinga
Global and U.S. Personalized Cancer Vaccines Market Generated - openPR.com
Global Cancer Vaccines Market to Surpass USD 15.00 Billion by 2032, Unlocking Over USD 10 Billion in New Growth Opportunities | MarketsandMarkets™. - GlobeNewswire Inc.
The 3 Things That Matter for Moderna Now - AOL.com
ASR Vermogensbeheer N.V. Buys Shares of 21,647 Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Is Moderna Inc. gaining market shareGame-Changing Investment Alerts - mustnews.co.kr
Research Analysts Offer Predictions for Moderna Q3 Earnings - MarketBeat
54,198 Shares in Moderna, Inc. (NASDAQ:MRNA) Acquired by ABC Arbitrage SA - MarketBeat
Envestnet Asset Management Inc. Sells 12,212 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
IBM and Moderna have simulated the longest mRNA pattern without AI — they used a quantum computer instead - Live Science
LPL Financial LLC Grows Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
UTMB, Moderna hit with vaccine research cancellation month after publishing new mRNA data - The Business Journals
Moderna to Cut 10% of Staff to Offset Slowing Covid Business - MSN
OVERSEA CHINESE BANKING Corp Ltd Has $1.16 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
XTX Topco Ltd Purchases 27,237 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Is Cutting 10,000 Jobs as Its Business Erodes. How Should You Play MRNA Stock Here? - Barchart.com
Is Moderna Stock A Sell After Cutting Its Sales Outlook — Again? - Investor's Business Daily
Moderna to slash 10% of workforce as biotech cuts costs, Covid shot sales slow - MSN
Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Banco Santander S.A. - MarketBeat
Moors & Cabot Inc. Reduces Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
RFK Jr. ends mRNA vaccine support; Moderna, other Mass. firms affected - WCVB
US HHS cancels 22 BARDA mRNA vaccine contracts - BioWorld MedTech
Public health experts dismayed by RFK Jr.'s defunding of mRNA vaccine research : ShotsHealth News - NPR
Moderna’s stock takes a hit as RFK Jr. backs out of some mRNA vaccine deals - MSN
HHS abandons mRNA vaccine research - BioPharma Dive
US health agency to wind down mRNA vaccine development - Reuters
The intrapreneur edge: What we learned at Moderna about the need to act like a startup - The Globe and Mail
Robust Growth in Mrna Therapeutics Process Development Market - openPR.com
UK Court of Appeal Confirms Moderna’s EP’949 Patent is Valid and Infringed by Pfizer/BioNTech - Amarillo Globe-News
RFK Jr. Axes 22 mRNA Vaccine Projects Under BARDA - BioSpace
HHS halts funding for mRNA vaccine activities (MRNA:NASDAQ) - Seeking Alpha
RFK Jr. Halts $500 Million In mRNA Vaccine Projects Backed By Pfizer, Moderna: 'We're Prioritizing Safer, Broader Strategies' - Benzinga
Moderna Stock: Is Wall Street Bullish or Bearish? - Yahoo Finance
Banque Cantonale Vaudoise Buys Shares of 14,589 Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):